1. Шилов Е.М., Фомин В.В., Швецов М.Ю. Хроническая болезнь почек. Терапевт. арх. 2007; 79 (6): 75–8.
2. Смирнов А.В. и др. Эпидемиология и социально-экономические аспекты хронической болезни почек. Нефрология. 2006; 10 (1): 7–13.
3. Couser WG et al. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int Nature Publishing Group 2011; 80 (12): 1258–70.
4. Nahas A, Bello A. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331–40.
5. Мухин Н.А. Снижение скорости клубочковой фильтрации – общепопуляционный маркер неблагоприятного прогноза. Терапевт. арх. 2007; 79 (6): 1–10.
6. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Под ред. А.В.Смирнова. Нефрология. 2012; 16 (1): 15–89.
7. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 (Suppl. 1); 39 (2): S1–266.
8. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013; 3 (1): 1–150.
9. Национальные рекомендации. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Под ред. В.С.Моисеева, Н.А.Мухина. Клин. нефрология. 2014; 2: 4–29.
10. U.S. Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. MD Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2013.
11. The Kidney Early Evaluation Prorgam (KEEP). KEEP 2012. Summary figures and analytical methods. Am J Kidney Dis 2012; 61 (4): S33–56. Suppl. 2.
12. Verhave JC et al. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 2005; 67 (5): 1967–73.
13. De Almeida EF et al. Evaluation of an instrument for screening patients at risk for chronic kidney disease: testing SCORED (Screening for Occult Renal Disease) in a Portuguese population. Kidney Blood Press Res 2012; 35 (6): 568–72.
14. Imai E et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp 2007.
15. Singh AK et al. Epidemiology and risk factors of chronic kidney disease in India – results fr om the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrology 2013; 14 (1): 114.
16. Антонова Т.Н. и др. К вопросу о распространенности хронической болезни почек среди пожилых лиц в г. Москве и ее связи с сердечно-сосудистой патологией. Нефрология и диализ. 2011; 13 (3): 353–4.
17. Шалягин Ю.Д. и др. Снижение скорости клубочковой фильтрации как маркер хронической болезни почек: частота встречаемости и клинические ассоциации (по данным обследования пациентов терапевтического профиля, госпитализированных в Коломенскую ЦРБ. Сб. тезисов VII Съезда Научного общества нефрологов России, 19–22 октября 2010 г. 
М., 2010; с. 140–1.
18. Серов В.А. и др. Возрастные и гендерные особенности распространенности хронической болезни почек среди больных с хронической сердечной недостаточностью. Нефрология и диализ. 2009; 11 (4): 332–5.
19. Schiffrin E, Lipman M, Mann J. Chronic kidney disease effects on the cardiovascular system. Circulation 2007.
20. Ritz E, McClellan W. Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences. J Am Soc Nephrol 2004; 15 (3): 513–6.
21. Vanholder R, Massy Z, Argiles A. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial 2005.
22. Кутырина И.М. и др. Факторы риска сосудистых осложнений у больных на додиализной стадии хронической почечной недостаточности. Терапевт. арх. 2006.
23. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective. Kidney Int 2006.
24. Милованова Л.Ю. и др. Механизмы нарушения фосфорно-кальциевого гомеостаза в развитии сердечно-сосудистых осложнений у больных хронической болезнью почек. Роль фактора роста фибробластов-23 (FGF-23) и Klotho. Терапевт. арх. 2010; 82 (6): 66–72.
25. Добронравов В.А. Современный взгляд на патофизиологию вторичного гиперпаратиреоза. Роль фактора роста фибробластов 23 и klotho. Нефрология. 2011; 15 (4): 11–20.
26. Weiner DE et al. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol 2007; 50 (3): 217–24.
27. Go AS et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351 (13): 1296–305.
28. Hallan SI, Stevens P. Screening for chronic kidney disease: which strategy? J Nephrol 2010; 23 (2): 147–55.
29. De Jong PE et al. Screening for chronic kidney disease: wh ere does Europe go? Clin J Am Soc Nephrol 2008; 3 (2): 616–23.
30. Qaseem A et al. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2013; 159 (12): 835–47.
31. National Collaborating Centre for Chronic Conditions. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. Royal Coll. London 2008; p. 204.
32. Levin A et al. Guidelines for the management of chronic kidney disease. Clinical guidelines of Canadian Society of Nephrology. Can Med Assoc J 2008; 179 (11): 1154–62.
33. Król E et al. Early detection of chronic kidney disease: results of the PolNef study. Am J Nephrol 2009; 29 (3): 264–73.
34. Levey A, Stevens L, Schmid C. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009.
35. Нагайцева С.С. и др. Исследование альбуминурии как маркера хронической болезни почек у взрослого трудоспособного населения. Альманах клин. медицины. 2014; 30: 37–45.
36. De Lima AO et al. Population screening for chronic kidney disease: a survey involving 38,721 Brazilians. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc 2012; 27 (Suppl. 3): iii135–8.
37. Нагайцева С.С. и др. Оценка альбуминурии методом тест-полосок с целью раннего выявления хронической болезни почек у лиц с разной степенью риска (опыт центров здоровья Московской области). Терапевт. арх. 2013; 86 (6): 38–43.
38. Приказ от 03.12.2012 №1006н Минздрава России «Об утверждении порядка проведения диспансеризации определенных групп взрослого населения».
39. Anandarajah S et al. The validity of searching routinely collected general practice computer data to identify patients with chronic kidney disease (CKD): a manual review of 500 medical records. Nephrol Dial Transplant 2005; 20 (10): 2089–96.
40. Lotan Y et al. Impact of fluid intake in the prevention of urinary system diseases: a brief review. Curr Opin Nephrol Hypertens 2013; 22 (1): S1–10. Suppl. 1.
41. Clark WF et al. Urine volume and change in estimated GFR in a community-based cohort study. Clin J Am Soc Nephrol 2011; 6 (11): 2634–41.
42. Sontrop JM et al. Association between water intake, chronic kidney disease, and cardiovascular disease: a cross-sectional analysis of NHANES data. Am J Nephrol 2013; 37 (5): 434–42.
43. Мухин Н.А. и др. Хронические прогрессирующие нефропатии и образ жизни современного человека. Терапевт. арх. 2004; 76 (9): 1–9.
44. Балкаров И. и др. Формирование артериальной гипертонии при уратном тубулоинтерстициальном поражении почек. Терапевт. арх. 1999; 6: 23–7.
45. Shvetsov M et al. Uric acid and arterial hypertension. J Vasc Res 1996; 33 (2): 40.
46. Verdecchia P, Schillaci G, Reboldi G. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension the PIUMA study. Hypertension 2000.
47. Filiopoulos V, Hadjiyannakos D, Vlassopoulos D. New insights into uric acid effects on the progression and prognosis of chronic kidney disease. Ren Fail 2012; 34 (4): 510–20.
48. Stellato D et al. Uric acid: a starring role in the intricate scenario of metabolic syndrome with cardio-renal damage? Intern Emerg Med 2012; 7 (1): 5–8.
49. Sedaghat S et al. Serum uric acid and chronic kidney disease: the role of hypertension. PLoS One 2013; 8 (11): e76827.
50. Щербак А.В. и др. Гиперурикемия и проблема хронической болезни почек. Терапевт. арх. 2013; 86 (6): 100–4.
51. Levey A et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80: 17–28.
52. Nitsch D et al. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ 2013; 346: f324.
53. Hallan SI et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA 2012; 308 (22): 2349–60.
54. Mahmoodi BK et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012; 380 (9854): 1649–61.
55. Fox CS et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380 (9854): 1662–73.
56. Moynihan R, Glassock R, Doust J. Chronic kidney disease controversy: how expanding definitions are unnecessarily labelling many people as diseased. BMJ 2013; 347: f4298.
57. Molitoris B. Screening: Screening for kidney disease – a lost opportunity. Nat Rev Nephrol Nature Publishing Group 2014; 10 (1): 6–8.
58. Maschio G et al. Effect of the Angiotensin-Converting – Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency. 
N Engl J Med 1996; 334 (15): 939–45.
59. Ruggenenti P et al. Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney Int Suppl 1997; 63: S54–7.
60. De Jong PE, Navis G. Proteinuria lowering needs a multifactorial and individualized approach to halt progression of renal disease. Nat Clin Pract Nephrol 2008; 4 (12): 654–5.
61. Добронравов В.А., Смирнов А.В., Каюков И.Г. Многогранная альбуминурия: аспекты клинического значения. Нефрология. 2009; 13 (3): 33–9.
62. Чазова И.Е. и др. Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Системные гипертензии. 2010; 3: 5–26.
63. Дедов И.И., Шестакова М.В. Сахарный диабет и артериальная гипертензия. Мед. информ. агентство, 2006.
64. Дедов И.И., Шестакова М.В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 2013; 6: 120.
65. Black C et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess 2010; 14 (21): 1–184.
66. Klag MJ et al. Blood pressure and end-stage renal disease in men. 
N Engl J Med 1996; 334 (1): 13–8.
67. Klahr S et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330 (13): 877–84.
68. European Society of Hypertension – European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21 (6): 1011–53.
69. Chobanian A, Bakris G, Black H. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289 (19): 2560–73.
70. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1–290.
71. Appel LJ et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363 (10): 918–29.
72. Sarnak MJ et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142 (5): 342–51.
73. Ruggenenti P et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365 (9463): 939–46.
74. Lv J et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med 2012; 9 (8): e1001293.
75. James P et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2013; 1097: 1–14.
76. Weber M et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the american society of hypertension and the international society of hypertension. J Clin Hypertens (Greenwich) 2014; 16 (1): 14–26.
77. Klahr S, Levey A, Beck G. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. 
N Engl J 1994.
78. Lv J et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. Can Med Assoc J 2013; 185 (11): 949–57.
79. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2012; 2 (5).
80. Mancia G et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the Euro­-
pean Society of Cardiology (ESC). Eur Heart J 2013; 34 (28): 
2159–219.
81. Jafar T et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003.
82. Nangaku M, Fujita T. Activation of the renin-angiotensin system and chronic hypoxia of the kidney. Hypertens Res 2008; 31 (2): 175–84.
83. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008; 74 (7): 867–72.
84. Covic A, Goldsmith D. Ambulatory blood pressure monitoring: an essential tool for blood pressure assessment in uraemic patients. Nephrol Dial Transplant 2002; 17 (10): 1737–41.
85. Velez JCQ. The importance of the intrarenal renin-angiotensin system. Nat Clin Pract Nephrol 2009; 5 (2): 89–100.
86. Drawz PE, Rosenberg ME. Slowing progression of chronic kidney disease. Kidney Int (Suppl.) Int Soc Nephrology 2013; 3 (4): 372–6.
87. Kobori H et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59 (3): 251–87.
88. Ruggenenti P et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 1998; 352: 1252–6.
89. Brenner B et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J 2001; 345: 861–9.
90. Lewis E et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. 
N Engl J 2001; 345 (12): 851–60.
91. Berl T. Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers. Nephrol Dial Transplant 2008; 23 (8): 2443–7.
92. Bos H et al. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int Suppl 2000; 75: S32–7.
93. Perna A et al. ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int 2000; 57: 274–81.
94. Ruggenenti P et al. ACE Inhibitors to Prevent End-Stage Renal Disease: When to Start and Why Possibly Never to Stop: A Post Hoc Analysis of the REIN Trial Results 2001; p. 2832–7.
95. Mann JFE et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372 (9638): 547–53.
96. Fried LF et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369 (20): 1892–903.
97. Bakris GL et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007; 72 (7): 879–85.
98. Parving H-H et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 2012; 13 (3): 387–93.
99. Fried LF et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013; 369 (20): 1892–903.
100. Maione A et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant 2011; 26 (9): 2827–47.
101. Bolignano D et al. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane database Syst Rev 2014; 4: CD007004.
102. Kim-Mitsuyama S, Ogawa HMK. An angiotensin II receptor blocker – calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. Kidney Int 2013; 83: 167–76.
103. Леванковская Е.И. и др. Инсулинорезистентность как ранний предиктор неблагоприятного течения хронической болезни почек недиабетической этиологии. Нефрология и диализ. 2010; 12 (2): 74–81.
104. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int Suppl 2013; 3 (3): 259–305.
105. Шило В.Ю. Селективная активация VDR – новаторский подход к профилактике и лечению вторичного гиперпаратиреоза, кардио- и ренопротекции. Клин. нефрология. 2012; 2: 32–41.
106. Добронравов В.А. и др. Национальные рекомендации по минеральным и костным нарушениям при хронической болезни почек. Нефрология и диализ. 2011; 13 (1): 33–51.
107. Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int 2009; 76 (Suppl. 113): S1–130.
108. Милованов Ю.С., Милованова Л.Ю., Козловская Л.В. Нефрогенная анемия: влияние на сердечно-сосудистую систему и прогрессирование хронической болезни почек. Клин. нефрология. 2010; 6: 7–18.
109. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int 2012; 2 (4).
110. Drüeke T, Locatelli F, Clyne N. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355 (20): 2071–84.
111. Singh A et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085–98.
112. Stengel B et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003; 14 (4): 479–87.
113. Ritz E et al. Salt – A Potential «Uremic Toxin»? Blood Purif 2005.
114. Fouque D et al. Nutrition and chronic kidney disease. Kidney Int 2011.
115. Moore LW et al. The mean dietary protein intake at different stages of chronic kidney disease is higher than current guidelines. Kidney Int. Int Soc Nephrology 2013; 83 (4): 724–32.
116. Ikizler TA et al. Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int. Int Soc Nephrology 2013; 84 (6): 1096–107.
117. Garneata L, Mircescu G. Effect of low-protein diet supplemented with keto acids on progression of chronic kidney disease. J Ren Nutr 2013; 23 (3): 210–3.
118. Kuznik A, Mardekian J, Tarasenko L. Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001–2010. BMC Nephrology 2013; 14 (1): 132.
119. Ruggenenti P et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 2008; 19: 1213–24.
120. Richards N et al. Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes. Nephrol Dial Transplant 2008; 23 (2): 549–55.
121. Turner JM et al. Treatment of chronic kidney disease. Kidney Int. Int Soc Nephrology 2012; 81 (4): 351–62.
122. Tayek JA, Kalantar-Zadeh K. The extinguished BEACON of bardoxolone: not a Monday morning quarterback story. Am J Nephrol 2013; 37 (3): 208–11.

М.Ю.Швецов

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России